3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
8
Breast Neoplasms
6
Prostatic Neoplasms
5
Triple Negative Breast Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Fallopian Tube Neoplasms
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms, Castration-Resistant
2
Lung Neoplasms
2
Glioma
2
Glioblastoma
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Metastatic Castration-sensitive Prostate Cancer
1
Laryngeal Diseases
1
Hereditary Sensory and Autonomic Neuropathies
1
Endometrial Neoplasms
1
Disease Progression
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Interventions
Bevacizumab
30
pembrolizumab
29
Oxaliplatin
28
Leucovorin
25
Fluorouracil
24
Irinotecan
22
Cetuximab
22
Capecitabine
19
Nivolumab
15
Specimen Handling
12
atezolizumab
11
Panitumumab
11
Colonoscopy
9
Carboplatin
9
regorafenib
8
Biopsy
8
trifluridine tipiracil drug combination
7
Trifluridine
7
Paclitaxel
7
Aspirin
7
balstilimab
6
Standard of Care
6
Cisplatin
6
tislelizumab
5
encorafenib
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Immunoglobulin G
5
Folfox protocol
5
Disulfides
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Colorectal Neoplasms
×
niraparib
×
Clear all
NCT03983993
2026-01-05
NIPAVect
Emory University
Phase 2
Active not recruiting
26 enrolled
8 charts